From the Journals
From the Journals
Liver transplant in CRC: Who might benefit?
“It seems likely that there is a small group of patients with unresectable colorectal liver metastases who should be considered for transplant,...
From the Journals
Alcohol consumption may not influence breast cancer prognosis, study
The findings could help in developing specific guidelines related to the prevention of breast cancer recurrence and death in survivors.
From the Journals
Sugary drinks may up risk for liver cancer, liver disease death
“Regardless of whether this is a surrogate marker for liver disease risk (such as fatty liver disease) or a consequence of the drink itself, it is...
From the Journals
Isometric exercise found optimal for lowering blood pressure?
The findings support the development of new exercise guidelines for blood pressure control, the authors said.
From the Journals
Female CRC survivors may experience long-term GI symptoms
“Our findings shed light on the importance of psychosocial support as well as lifestyle interventions (specifically nutritional management) in...
From the Journals
Older women risk overdiagnosis with mammograms: Study
Overdiagnosis carries the risks of complications from overtreatment, plus financial and emotional hardships.
From the Journals
Scalp cooling for chemo hair loss strikes out with patients
“The efficacy and tolerability of [scalp cooling] applied in a clinical routine setting ... appeared to be limited.”
From the Journals
For CLL, BTKi combo bests chemoimmunotherapy
Phase 3 FLAIR trial yields more evidence that younger patients fared better with two-drug combo than with FCR, the once-standard therapy.
From the Journals
Antibody shows promise in preventing GVHD
In translational research that shows potential for humans, an antibody blockade of the Notch signaling pathway prevents graft-versus-host-disease...
From the Journals
PPIs may curb benefits of palbociclib in breast cancer
“The findings suggest that taking PPIs with palbociclib may interrupt the full therapeutic benefits of palbociclib,” the authors conclude.
From the Journals
MM: Newest IKEMA results back isatuximab
Adding isatuximab to carfilzomib and dexamethasone creates ‘another effective triplet’ for relapsed/refractory multiple myeloma.